Previous 10 | Next 10 |
Live Webcast Scheduled to Begin at 9 am EDT Today Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation ...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Th...
2024-04-04 10:16:45 ET More on Aldeyra Therapeutics Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects Aldeyra gains as Oppenheimer upgrades on revise...
2024-04-03 09:01:58 ET More on Aldeyra Therapeutics Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects Aldeyra gains on plans for AbbVie-partnered eye...
2024-03-28 13:42:43 ET More on Aldeyra Therapeutics Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects Seeking Alpha’s Quant Rating on Aldeyra ...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application...
2024-03-24 00:46:24 ET Summary Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in ...
2024-03-07 17:00:16 ET More on Aldeyra Therapeutics Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects Abbvie extends option agreement with Aldeyra for dry eye candidate Read the full article on Seeking Alpha For further det...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat ...
2024-01-28 02:56:00 ET Summary Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunctivitis. The company has an option agreement with A...
News, Short Squeeze, Breakout and More Instantly...
Aldeyra Therapeutics Inc. Company Name:
ALDX Stock Symbol:
NASDAQ Market:
Aldeyra Therapeutics Inc. Website:
Live Webcast Scheduled to Begin at 8:00 a.m. ET Today Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new ...
Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabo...
Event Scheduled for Thursday, June 20 at 8:00 a.m. ET Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will h...